Insulin Degludeg / Insulin Aspart BID injection therapy versus GLP-1 analogue Liraglutide and Insulin Deguldec combination therapy in Tochigi

Trial Profile

Insulin Degludeg / Insulin Aspart BID injection therapy versus GLP-1 analogue Liraglutide and Insulin Deguldec combination therapy in Tochigi

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Insulin degludec (Primary) ; Liraglutide (Primary) ; Insulin aspart
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms IDEAL
  • Most Recent Events

    • 12 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 05 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top